Key Takeaways
- Shares of Tempus AI jumped approximately 7%, reaching $82.24 following impressive quarterly results.
- The company delivered $382.49 million in revenue, marking a 22% year-over-year increase and surpassing analyst projections.
- Adjusted loss per share came in at just $0.04, significantly narrower than the expected $0.14.
- CEO Eric Lefkofsky divested 250,000 shares worth $19.4 million through a pre-arranged 10b5-1 trading plan.
- Analyst sentiment remains mixed with a Hold consensus and an average price target of $69.63.
Shares of Tempus AI (TEM) advanced 7% this week, closing at $82.24 as investors digested simultaneous events: significant insider stock sales and better-than-anticipated quarterly financial results. The precision medicine technology firm exceeded Wall Street’s projections for both top and bottom lines.
The shares have recovered impressively, gaining 30% year-to-date following a challenging period that witnessed prices tumble nearly 50% from their previous peak levels.
Quarterly revenue reached $382.49 million, representing a robust 22% gain compared to the corresponding quarter in the prior year.
The company registered an adjusted loss of just $0.04 per share, substantially better than the Street’s consensus estimate calling for a $0.14 per share loss.
Despite the positive momentum, profitability remains elusive. The firm accumulated a net loss of $254.4 million throughout the trailing twelve-month period.
Executive Team Offloads Shares Through Pre-Set Trading Arrangements
Chief Executive Officer Eric Lefkofsky divested 250,000 shares on September 22 at an average execution price of $77.47. This transaction generated approximately $19.4 million in proceeds and reduced his direct ownership stake by roughly 71%.
Chief Accounting Officer Ryan Bartolucci participated in the selling activity as well, disposing of 7,062 shares valued at $529,650 on September 17. Following this transaction, his direct holdings stand at 60,804 shares.
Additional members of the executive team also executed sales. CEO Ryan Fukushima sold 700 shares generating $49,000, while Executive Vice President Andrew Polovin offloaded 2,951 shares for $221,325.
These transactions occurred under pre-established Rule 10b5-1 trading plans. Such arrangements are configured well in advance, ensuring that execution timing remains independent of any material non-public information or company developments.
Across the past three-month period, company insiders collectively sold approximately $73.1 million in Tempus AI stock. Despite these sales, corporate insiders retain ownership of roughly 24% of outstanding shares.
Analyst Community Delivers Mixed Assessment
Street sentiment on Tempus AI remains divided. Current coverage includes eleven Buy ratings, nine Hold recommendations, and two Sell ratings from financial analysts.
This distribution produces a consensus Hold recommendation. The mean price objective stands at $69.63, notably below current trading levels.
Multiple research firms have revised their outlooks recently. BTIG Research elevated its target from $70 to $80 while reaffirming a Buy stance.
HC Wainwright increased its price objective from $56 to $66, continuing to recommend the stock as a Buy. Raymond James established an $80 valuation target.
However, not all analysts share this optimism. UBS Group initiated research coverage with a Neutral position and $70 target price.
Stifel Nicolaus reduced its target from $60 down to $50 accompanied by a Hold rating. Wolfe Research launched coverage with a Peer Perform designation.
Trading activity surged during the recent price movement. Thursday’s session recorded approximately 8.5 million to 10.7 million shares traded, significantly exceeding the typical daily volume of around 6.1 million units.
The company’s market valuation currently ranges between $14 billion and $15 billion based on intraday fluctuations. The 52-week trading range extends from a low of $40.77 to a high of $104.32.
Institutional investors control 24.22% of outstanding shares. Notable recent activity includes Whittier Trust Co., which expanded its position by 190% during Q1, and CoreCap Advisors, which increased its holdings by nearly 293% in the second quarter.
Tempus AI’s technology platform specializes in oncology and precision medicine applications. The platform integrates clinical workflows with diagnostic laboratory services and analytical tools utilized by healthcare providers throughout the United States.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
